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a  b  s  t  r  a  c  t
Background: Carbapenem-resistant Acinetobacter baumannii (CRAb) is an important cause of
nosocomial infections especially in intensive care units. This study aimed to assess clinical
aspects and the genetic background of CRAb among ICU patients at a Brazilian teaching
hospital.
Methods: 56 critically ill patients colonized or infected by CRAb, during ICU stay, were
prospectively assessed. Based on imipenem MIC ≥ 4 g/mL, 28 CRAB strains were screened
for  the presence of genes encoding metallo--lactamases and OXA-type -lactamases. The
blaOXA-type genes were characterized by PCR using primers targeting ISAba-1 or -3. Genetic
diversity of blaOXA-positive strains was determined by ERIC-PCR analysis.
Results: Patient’s mean age (±SD) was 61 (±15.1), and 58.9% were male. Eighty-percent of
the  patients presented risk factors for CRAb colonization, mainly invasive devices (87.5%)and previous antibiotic therapy (77.6%). Thirty-three patients died during hospital stay
(59.0%). Resistance to carbapenems was associated with a high prevalence of blaOXA-23
(51.2%) and/or blaOXA-143 (18.6%) genes. ERIC-PCR genotyping identiﬁed 10 clusters among
OXA-producing CRAb. Three CRAb strains exhibited additional resistance to polymyxin B
(MIC ≥ 4 g/mL), whereas 10 CRAb strains showed tigecycline MICs > 2 g/mL.∗ Corresponding author.
E-mail address: francellineves@gmail.com (F.C. Neves).
http://dx.doi.org/10.1016/j.bjid.2016.08.004
1413-8670/© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Conclusions: In this study, clonally unrelated OXA-123- and OXA-143-producing A. baumannii
strains in ICU patients were strongly correlated to colonization with infected patients being
associated with a poor outcome.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is











































cinetobacter baumannii is a Gram-negative non-fermentative
occobacillus that has gained growing notoriety as a nosoco-
ial pathogen, showing patterns of increasing resistance to
ntimicrobial drugs and disinfectants. These organisms are
mplicated in a diverse array of infections, especially in inten-
ive care units (ICUs) associated with countless outbreaks.1,2
lassically, carbapenems plays a crucial role in the treatment
f serious nosocomial infections due to A. baumannii,  but
his scenario has changed substantially in the last decade,
ith an increasing prevalence of carbapenem-resistant and
ultidrug-resistant isolates.3
Carbapenem resistance in A. baumannii is mainly due to
he presence of -lactamases (class B metallo--lactamases
 MBL, or class D OXA-type -lactamases – oxacillinases –
XA), to the loss of outer membrane proteins,4 and to altered
enicillin-binding proteins (PBP).5 OXA-type -lactamases are
hromosomal enzymes that in A. baumannii can be intrin-
ic (e.g., OXA-51-like) or, more  frequently, acquired (e.g.,
XA-23-like, OXA-24-like, OXA-58-like).6 Outbreaks of OXA-
3-producing A. baumannii have been reported in some
razilian hospitals. Moreover, a new oxacillinase, OXA-143-
ike, was recently described in this country.3,7–9
Only few studies concerning the molecular basis of car-
apenem resistance in A. baumannii,  as well as the clinical
mpact of these resistant strains on patient outcomes, have
een reported, despite the growing importance of these strains
n ICUs of Brazilian hospitals.3,7,8
Thus, the aim of this study was to investigate the
enetic determinants of carbapenem resistance and the clonal
elatedness of carbapenem-resistant A. baumannii (CRAb)
trains isolated from patients admitted to a Brazilian intensive
are unit.
aterials  and  methods
tudy  setting  and  population
his study was conducted in a medical ICU of a 500-bed
ertiary care teaching hospital, afﬁliated to the Federal Uni-
ersity of Minas Gerais (UFMG), in Brazil. All adult (≥18
ears) patients colonized or infected by CRAb during ICU stay
etween December 2009 and December 2010 were assessed
or potential inclusion in the study. Demographic and clin-
cal data were retrospectively obtained from a data bank
rospectively ﬁlled, which is used for research and admin-
strative issues. Colonization was deﬁned by the presence of
RAb on skin, on mucous membranes, in open wounds, or inlicenses/by-nc-nd/4.0/).
excretions or secretions obtained during routine surveillance
for multiresistant bacteria. According to the protocol followed
in our ICU, surveillance swabs are obtained upon admission
and weekly up to discharge from the unit.10 Infection was
deﬁned as the presence of CRAb identiﬁed in specimens asso-
ciated with infection reported according to NHSN criteria. For
both cases, colonization and infection, only the ﬁrst isolate
was considered.
Ethical  aspects
This study was approved by the Institutional Research Ethical
Committee. Privacy was guaranteed and patients were iden-
tiﬁed by their hospital registration numbers. Only researchers
had access to the information of the enrolled patients.
Variables  and  deﬁnitions
Baseline demographic and clinical data were obtained from
medical charts. Colonization was deﬁned as the presence of
microorganisms on skin, on mucous membranes, in open
wounds, or in excretions or secretions, unassociated with clin-
ical signs or symptoms of infection during routine surveillance
or specimens not associated to infections.10 Infection was
deﬁned as identiﬁcation of CRAb in clinical specimens asso-
ciated with infection reported according to NHSN criteria site.
Baseline demographic and clinical data were obtained from
medical charts.
Laboratory  tests
CRAb  strains  and  antimicrobial  susceptibility  testing
CRAb isolates were identiﬁed using the VITEK 2 system
(bioMérieux, France®). Antimicrobial screening was carried
out using the Kirby-Bauer disk diffusion method.11 The con-
ﬁrmatory susceptibility test was performed using the agar
dilution method for imipenem, tigecycline, and polymyxin
B, as recommended by the Clinical and Laboratory Stan-
dards Institute and the Food and Drug Administration (FDA).11
FDA-approved tigecycline breakpoints for Enterobacteriaceae,
were applied to all isolates (susceptible ≤2 g/mL; resistant
≥8 g/mL).
Detection  of  carbapenemasesA screening test for MBL production was performed using the
double-disk synergy test (DDST), as recommended by Arakawa
et al. Phenotypic detection of MBLs was performed using
i s . 2 0 1 6;2  0(6):556–563
Table 1 – Demographic data of ICU patients with CRAb.
Parameters n (±SD) %
Patient characteristics
Age (years) 61.0 ± 15.1 –
Male/female 33/23 –
ICU stay (days) 18.7 ± 16.5 –
APACHE II score 14.3 ± 6.0 –
Co-morbidities (%) 47 83.9
Underlying pathology
Hematological malignancies 3 5.3
Solid tumor 2  3.6
Steroid use 5  8.9
Diabetes mellitus 19 33.9
Chronic kidney disease 13 23.2
Cardiovascular disease 14 25.0
Chronic obstructive pulmonary disease 10 17.8
Liver failure (Child B or C) 6 10.7
Previous invasive devices 49 87.5
Central venous catheter 38 67.9
Foley catheter 46 82.1
Mechanical ventilation 46 82.1
Previous antimicrobial use 44 78.6
Carbapenems 19 33.9
Cephalosporins 3rd Gen. 18 32.1
Cephalosporins 4th Gen. 15 26.8
Quinolones 9 16.0
-Lactamase inhibitors 12 21.4
Glycopeptides 15 26.8





Nosocomial infection 18 32.1
Site of infection
Intra-abdominal 1 5.6
Lungs (pneumonia) 10 55.5
Bloodstream (catheter-associated) 5 27.7
Bloodstream (primary) 1 5.6
Urinary tract 1  5.6
Progression of infection558  b r a z j i n f e c t d 
Etest® MBL  strips, following the manufacturer’s recommen-
dations (AB bioMérieux, St. Louis, MO, USA).
Polymerase  chain  reaction  (PCR)  ampliﬁcation  and  DNA
sequencing
Multiplex PCR was performed to investigate the genes encod-
ing the following carbapenemases: blaOXA-23-like, blaOXA-51-like,
blaOXA-58-like, blaOXA-24-like, blaOXA-143-like, blaVIM-like, blaIMP-1,
and blaIMP-like. Speciﬁc primers were used to identify the inser-
tion sequences (ISAba1 and ISAba3).12
ERIC-PCR  typing
The genetic similarity of A. baumannii isolates was determined
using Enterobacterial Repetitive Intergenic Consensus-PCR
(ERIC-PCR). A similarity matrix was calculated using the
DICE coefﬁcient with 2% tolerance. Percent similarity deter-
mination, cluster calculation, and subsequent dendrogram
construction were performed using the Bio Numerics
software.13
Statistical  analysis
Clinical and epidemiological characteristics were described.
The distribution of continuous variables was tested, and
their normal or non-normal distributions presented as
mean ± standard deviation or median (IQR), respectively.
Categorical variables were analyzed using frequencies and
percentages. Associations between -lactamases and ICU
mortality were tested using chi-square test. The Statistical
Package for the Social Sciences (SPSS), version 15.0 (Chicago,
IL), was used for all analyses. Statistical signiﬁcance was deter-
mined as p ≤ 0.05 and comparative analyses are presented
with the 95% conﬁdence interval (95% CI).
Results
Patients  characteristics
Overall, 867 patients were admitted on the ICU during the
study period, 56 of whom had positive results for carbapenem-
resistant A. baumannii cultures in clinical samples (e.g., blood,
tracheal aspirate, urine, or wound secretion) or surveillance
swabs. Forty-three out of the 56 strains were subjected to
quantitative testing, as well as phenotypic and genotypic
resistance evaluation. The characteristics of patients infected
or colonized by CRAb are shown in Table 1. From a total of
56 patients, 38 (67.9%) were colonized and 18 (32.1%) were
infected with CRAb. Table 2 presents the type of CRAb isolation
(colonization or infection), site of infection, and patient out-
come. The majority of patients (83.9%) had comorbidities, and
the most common condition was diabetes mellitus (33.9%).
Eighty-seven percent of the patients had previously received
invasive devices and 78.6% had received antimicrobial therapy,
mainly cephalosporins (58.9%), carbapenems (33.9%), and gly-
copeptides (26.8%). Among the 18 infected patients, 10 (55.5%)
had pneumonia, six (33.3%) had bloodstream infections, one
(5.6%) had urinary tract infection, and one (5.6%) presented anDischarge 23 41.0
Death 33 59.0
intra-abdominal infection. Overall, 33 out of the 56 patients
(59%) died during hospital stay.
Phenotypic  antimicrobial  susceptibility  of  isolates
The antimicrobial susceptibility proﬁles of the CRAb iso-
lates, deﬁned by disk diffusion and agar dilution methods,
are presented in Table 3. Gentamicin turned out to be the
best antimicrobial in terms of susceptibility (33.9%), fol-
lowed by sulfamethoxazole/trimethoprim (21.4%). Resistance
to imipenem was conﬁrmed for only 58.1% of all A. bauman-
nii strains. Polymyxin and tigecycline resistance was seen in



























Table 3 – Clinical and microbiological characteristics of OXA-producing Acinetobacter baumannii strains isolated from ICU patients.
CRAb
strain

















IMP POL TIG Antimicrobial drugs
288 Nasal >32 1.0 1.0 AK, SAM, CFP, CTZ, CIP,
MER, PTZ
blaOXA-51, blaOXA-143 G2 M/71 12/02/09 23 Colonized/No 12/13/09 Death CVC + IUC + MV
295 Nasal >32 1.0 2.0 AK, SAM, CFP, CFZ, CIP,
MER, PTZ
blaOXA-51, blaOXA-143 G4 M/56 01/03/10 15 Colonized/Yes 01/19/10 Survival CVC + IUC + MV
296 Perianal >32 1.0 2.0 AK, SAM, CFP, CFZ, CIP,
MER, PTZ
blaOXA-51, blaOXA-143 H M/49 01/19/10 16 Colonized/No 01/19/10 Death –
297 Perianal >32 1.0 1.0 AK, SAM, ATM, CFP, CTZ,
CIP, GEN MER
blaOXA-51, blaOXA-143 I F/77 12/08/09 12 Colonized/Yes 01/19/10 Death CVC + IUC + MV
356 Nasal 4.0 0.5 <0.5 AK, SAM, ATM CFP, CTZ,
CIP, MER, PTZ, SUT
blaOXA-51, blaOXA-143,
blaOXA-23
F M/63 05/19/10 15 Colonized/Yes 05/19/10 Survival MV
384 Nasal >32 2.0 2.0 AK, SAM, CFP, CTZ, CIP,
GEN, MER, PTZ, SUT
blaOXA-51, blaOXA-143,
blaOXA-23
F M/58 05/13/10 9 Colonized/Yes 06/10/10 Survival CVC + IUC + MV
385 Blood >32 2.0 4.0 AK, SAM, CFP, CTZ, CIP,
GEN, MER, PTZ, SUT
blaOXA-51, blaOXA-143,
blaOXA-23
F M/75 06/11/10 10 NI-sepse/Yes 06/23/10 Death CVC + IUC + MV
390 Perianal 8.0 4.0 4.0 SAM, ATM, CFP, CTZ, CIP,
MER, PTZ, SUT
blaOXA-51, blaOXA-23 J1 F/45 07/20/10 15 Colonized/Yes 07/29/10 Survival CVC + IUC + MV
394 Nasal 16 1.0 4.0 AK, SAM, CFP, CTZ, CTX,
CIP, MER, PTZ, SUT
blaOXA-51, blaOXA-23 J1 F/83 07/10/10 15 Colonized/Yes 07/16/10 Death CVC + IUC + MV




I M/59 07/16/10 15 Colonized/Yes 07/28/10 Death CVC + IUC + MV
399 Perianal >32 8.0 4.0 SAM, ATM, CFP, CTZ, CIP,
GEN, MER, PTZ, SUT
blaOXA-51, blaOXA-23 F F/76 07/23/10 15 Colonized/No 07/24/10 Survival IUC
407 Perianal 16 2.0 4.0 AK, SAM, CFP, CTZ, CIP,
GEN, MER, PTZ, SUT
blaOXA-51, blaOXA-23 B M/20 07/27/10 10 Colonized/Yes 08/02/10 Survival CVC + IUC
408 Nasal 16 1.0 <0.5 AK, SAM, CFP, CTZ, CIP,
GEN, MER, PTZ, SUT
blaOXA-51, blaOXA-23 H M/68 07/28/10 18 Colonized/Yes 08/02/10 Death CVC + IUC + MV
414 Nasal >32 1.0 2.0 AK, SAM, ATM, CFP, CTZ,
CIP, MER, PTZ, SUT
blaOXA-51, blaOXA-23 H F/71 08/02/10 11 NI-sepse/No 08/07/10 Death CVC + IUC + MV
416 Perianal 16 1.0 4.0 AK, CFP, CTZ, CIP, GEN,
MER, PTZ
blaOXA-51, blaOXA-23 B F/68 08/02/10 20 Colonized/Yes 08/06/10 Death CVC + IUC + MV
417 Catheter 16 2.0 4.0 AK, SAM, ATM, CFP, CTZ,
CIP, PTZ
blaOXA-51, blaOXA-23 A M/47 08/03/10 20 NI-PNU/Yes 08/09/10 Survival CVC + IUC + MV
421 Catheter 16 1.0 4.0 AK, SAM, ATM, CFP, CTZ,
CIP, GEN, MER, PTZ


























Table 3 – (Continued)
CRAb
strain

















IMP POL TIG Antimicrobial drugs
436 Nasal 16 0.5 2.0 AK, ATM, CFP, CTZ, CIP,
MER, PTZ, SUT
blaOXA-51, blaOXA-23 K M/85 08/25/10 13 NI-PNU/No 09/01/10 Death CVC + IUC + MV
461 Nasal 16 0.5 <0.5 AK, SAM, CFP, CTZ, CIP,
MER, PTZ, SUT
blaOXA-51, blaOXA-23 K M/79 09/16/10 13 NI-PNU/Yes 13/10/10 Death CVC + IUC + MV
464 Nasal 16 1.0 2.0 AK, SAM, CFP, CTZ, CTX,
CIP, MER, PTZ
blaOXA-51, blaOXA-23 K F/85 08/27/10 – Colonized/Yes 10/03/10 Death CVC + IUC + MV
470 Nasal >32 0.5 2.0 AK, SAM, ATM, CFP, CTZ,
CTX, CIP, GEN, MER, PTZ,
SUT
blaOXA-51, blaOXA-23 D M/47 10/08/10 16 Colonized/Yes 10/15/10 Death CVC + IUC + MV
479 Catheter 16 4.0 2.0 AK, ATM, CFP, CTZ, CTX,
CIP, GEN, MER, PTZ, SUT
blaOXA-51, blaOXA-23 O F/65 09/30/10 13 Colonized/Yes 10/20/10 Survival CVC + IUC + MV
487 Perianal 16 0.5 4.0 AK, SAM, ATM, CFP, CTZ,
CIP, GEN, MER, PTZ, SUT
blaOXA-51, blaOXA-23 G M/53 10/17/10 9 Colonized/Yes 10/23/10 Survival CVC + IUC + MV
489 Nasal 4.0 1.0 4.0 AK, SAM, ATM, CFP, CTZ,
CIP, GEN, MER, PTZ
blaOXA-51, blaOXA-23 O M/64 10/22/10 10 NI-sepse/No 10/26/10 Death CVC + IUC + MV
503 Nasal 16 0.5 2.0 AK, SAM, ATM, CFP, CTZ,
CIP, MER, PTZ, SUT
blaOXA-51, blaOXA-23 O M/77 09/29/10 21 Colonized/Yes 11/18/10 Death CVC + IUC + MV
511 Nasal 16 1.0 2.0 SAM, ATM, CFP, CTZ, CIP,
GEN, MER, PTZ
blaOXA-51 O M/56 11/08/10 13 Colonized/No 11/21/10 Death –
515 Perianal 16 0.5 2.0 AK, SAM, ATM, CFP, CTZ,
CIP, MER, PTZ, SUT
blaOXA-51, blaOXA-23 K1 F/72 11/12/10 11 NI-PNU/Yes 11/22/10 Death –
544 Nasal 16 1.0 2.0 AK, SAM, ATM, CFP, CTZ,
CIP, GEN, MER, PTZ, SUT
blaOXA-51 D1 F/20 12/06/10 9 Colonized/No 12/24/10 Survival CVC + IUC + MV
IMP, imipenem; POL, polymyxin; TIG, tigecycline; AK, amikacin; SAM, ampicillin/sulbactam; ATM, aztreonam; CFP, cefepime; CTZ, ceftazidime; CTX, ceftriaxone; CIP, ciproﬂoxacin; GEN, gentamicin;
MER, meropenem; PTZ, piperacillin/tazobactam; SUT, sulfamethoxazole/trimethoprim; NI, nosocomial infection; PNU, pneumonia; ATM, previous antimicrobial therapy; CVC, central venous catheter;
IUC, indwelling urinary catheter; MV, mechanical ventilation.
a ISAba-1 was found upstream of the blaOXA-23 gene.
b ERIC-PCR ﬁngerprint patterns were analyzed using the Dice similarity coefﬁcient and the unweighted-pair group method using average linkages cluster method (BioNumeric software, Applied
Maths, Kortrijk, Belgium).

















































cb r a z j i n f e c t d i s .
The MBL  enzyme was not found in any of the 43 CRAb
trains by the double-disk synergy test (DDST).
olecular  characterization  of  CRAb  strains
he blaOXA-51 gene was detected in all studied strains, whereas
laOXA-23 was found in 22 (51.2%) and blaOXA-143was detected
n eight (18.6%) isolates. Of the 17 strains susceptible to
mipenem in the conﬁrmatory phenotypic tests, i.e., agar
ilution method, two presented blaOXA-23 and one presented
laOXA-143. Table 3 depicts the main clinical and microbiolog-
cal characteristics of the 56 patients harboring (colonized or
nfected by) OXA producing CRAb strains. Other resistance-
ncoding genes such as VIM and IMP-like were not found
mong the tested strains. Finally, two imipenem-resistant
trains did not display any of the acquired oxacillinases or
etallo--lactamases during the investigation.
olecular  typing
enotypic analysis of the CRAb isolates from 43 patients, using
he ERIC-PCR, identiﬁed 15 different patterns, with 90% simi-
arity according to dendrogram analysis. The main clusters (B,
, H, J, K, O) were observed in 25 (58.1%) CRAb isolates. Sensi-
ive and resistant strains were found for the same genotype
Table 3).
iscussion
arbapenem-resistant A. baumannii has emerged over the
ast decades as an important infection-causing microorgan-
sm in intensive care patients.1,2 Despite being considered
pportunistic, many  authors underline the negative impacts
temming from CRAb infections, probably due to the delay
o initiate appropriate antimicrobial therapy.14 However, in
pite of the high prevalence of this microorganism in hospitals
round the world, especially in Brazil, little is known about the
elationship between the presence of resistance genes and the
utcome of CRAb infected patients.
CRAb is an important microorganism that colonizes and
nfects patients in our intensive care unit. During this study
RAb was isolated from ∼10% of the patients and the main
eterminant of carbapenem resistance among A. baumannii
solates in this population was the production of oxacilli-
ases OXA-23 and OXA-143. Moreover, a polyclonal pattern
as observed among the studied strains.
This study presents limitations that are inherent to ret-
ospective analysis and the quality of data depended on the
linical records. Patient enrollment occurred during a limited
eriod of time, with small sample of patients evaluated. Addi-
ionally, molecular tests were done in ∼77% of cases (43/54)
nd even though carbapenem resistance was an inclusion
riteria for the study, only ∼60% of A. baumannii samples had
his resistance conﬁrmed by microdilution tests. The disk dif-
usion is a method of screening, with potential limitations as
nadequate drug concentration and lability of the drug on the
isk. Thus, transportation and disk storage in less than ideal
onditions may interfere in the results.156;2 0(6):556–563 561
In a study conducted in Brazil showed that none of the
evaluated brands distributed in Brazil presented satisfactory
performance.15 It is worth mentioning that some strains even
presenting a sensible proﬁle, but with elevated minimum
inhibitory concentration, had already genetic mutations (e.g.
OXA 23) related to resistance. In this case series only enzy-
matic mechanisms of resistance were investigated.
Patients colonized or infected by CRAb strains presented
a high hospital mortality rate (59%), although mortality could
not be attributed only to the presence of CRAb. This feature,
however, was not the focus of our study. Recently, Lemos et al.
(2013) observed in a meta-analysis that CRAb patients had an
increased mortality risk (OR-2.22; 95% CI: 1.66–2.98). These
authors included 16 studies and most of them referred to
infections due to CRAb, mainly bacteremia. Only one study
considered infected and colonized patients. Nevertheless,
most patients also presented a severe underlying illness and
received inappropriate empirical antimicrobial treatment.16
Treatment options for CRAb infections are scarce and gen-
erally employ polymyxins or tigecycline.17,18 In our study,
76.7% of the strains were susceptible to tigecyline, a lower
percentage than the 97.1% found by Rossi et al. in sam-
ples from Latin America.19 Regarding polymyxins (polymyxin
B and E), resistance to polymyxin B was observed in three
(7%) of the analyzed strains in this study (C> 4 g/mL, CLSI
2011). SENTRY – 2006 found 2.1% resistance to polymyxin in
Latin America.20 This ﬁnding is worrisome since polymyxins
are regarded as the major therapy options for treating CRAB
infections, despite their toxicity.21 Another important issue is
the variable therapeutic effectiveness of polymyxin on CRAB
(50–80%).18,22
In the present study, we found that the blaOXA-51 gene was
present in all strains studied, conﬁrming the A. baumannii
species. OXA-51 has weak carbapenemase activity, but poten-
tially increases the minimum inhibitory concentration (MIC)
when overproduced.23 Carbapenem resistance in A. baumannii
frequently results from the production of acquired oxacilli-
nases, such as OXA-23, OXA-24, and OXA-58, besides the less
frequent OXA-143 and OXA-72.24 The production of the car-
bapenemase OXA-23 has been frequently identiﬁed in CRAB
strains from patients admitted to Brazilian hospitals.25 In this
study, OXA-23 was the most commonly acquired carbapene-
mase (51.2%), followed by OXA-143, which was identiﬁed in
eight strains (18.6%). It is worth noting that OXA-143 was
described in 2009 by Higgins et al., and has so far only been
found in Brazilian hospitals.3,7,8
In our study, almost all CRAB strains presented at least one
acquired oxacillinase (OXA-23 or OXA-143), and only two  resis-
tant strains did not display any of the investigated enzyme
mechanisms. In this case, other resistance mechanisms may
be involved, such as efﬂux pumps, changes in outer mem-
brane proteins (OMPs) or changes in afﬁnity or expression of
penicillin-binding proteins (PBPs).1
Among the analyzed strains, 15 distinct clones were iden-
tiﬁed in six main related clusters, which characterizes a
polyclonal distribution but includes groupings with >90% sim-
ilarity. This fact is probably related to cross-transmission.
CRAb strain was ﬁrst identiﬁed in our institution in 2003, and
since then there has been an exponential increase in num-
ber of cases. HC/UFMG is a hospital of high complexity and











1562  b r a z j i n f e c t d 
public reference center. Thus, the hospital always receives
many patients who  are possibly colonized/infected with CRAb
from many  other services.
In the present study, three out of the four CRAb patients
with the K clone ultimately passed away. Moreover, the
blaOXA-23 gene was identiﬁed in all these CRAb strains. Due
to the small sample of patients and the heterogeneity of
their clinical and microbiological presentations, associations
regarding the production of oxacillinases and patient mortal-
ity could not be performed in this study.
Conclusions
Despite the limitations, this study showed that CRAb col-
onized or infected patients presented a high frequency of
comorbidities, with long hospital stays and increased hos-
pital morbidity. The strains studied showed a wide genetic
diversity with polyclonal dissemination pattern. The most
frequent resistance mechanism was the production of car-
bapenemases, notably OXA-23, but with cases of OXA-143
expression. Although the production of metallo--lactamases
was not identiﬁed, other mechanisms may be involved, as
there were resistant strains that did not express any gene
related to carbapenemases. Strains drug resistance proﬁle was
discordant in 40% of cases when using disk diffusion and agar
dilution methods. We also need to underscore that polymyxin
B resistance was higher than described in literature and this
may be a challenge for patient management, due to the limita-
tions of therapeutic options. In our view, prevention for MDR
infection is the key for better assisting patients in intensive
care unit and antimicrobial susceptibility tests need to present
more rigorous quality control. The increasing of polymixin
resistance also warrants a better approach.
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